EAST TAUNTON, Mass., Oct. 27, 2014 /PRNewswire/ -- OMNIlife science, Inc. (“OMNI”), an established medical technology company targeting the $15 billion global hip and knee replacement device market, announced it will exhibit its’ navigated robotic system, hip, and knee replacement technology at the American Association of Hip and Knee Surgeons (AAHKS) 24th Annual Meeting at the Sheraton Dallas Hotel in Dallas, Texas on November 6-9 in Booth #613. OMNI is a Bronze corporate partner of the organization.
George B. Cipolletti, President and CEO of OMNI, said, “We look forward to showcasing OMNINAV. It is the only FDA cleared surgical navigation system that employs robotic technology to enhance the surgeon’s implant placement for total knee replacements.”
Since the introduction of OMNINAV, more than 4,500 OMNIPLASTY procedures have been performed world-wide. OMNIPLASTY provides the surgeon with an integrated navigation robotic capability that optimizes knee implant alignment and placement specifically for each patient’s unique anatomy intra-operatively. The surgeon maintains control and makes all decisions regarding the total knee replacement while providing a patient specific surgery. Procedure preparation does not require any pre-operative imaging studies requiring radiation like a CAT scan or an extra patient procedure, an MRI. Both add additional costs and disruption for patients who need to make an extra appointment. OMNINAV is designed to reduce the instrumentation burden on hospitals for total joint replacement procedures. OMNI is developing system applications to support all major joint replacements, extremities, spine and sports medicine.
The AAHKS Annual Meeting provides a timely, peer-reviewed program that presents the current evidence-based approach to delivering hip and knee arthroplasty care. More than 1,300 orthopedic surgeons, fellows, residents and allied health professionals highly interested in primary and revision total joint arthroplasty are expected to attend.
OMNI is proud to sponsor a mini symposium on Friday, November 7th focused on 23 Hour Total Joint Arthroplasty. This dynamic session led by Dr. Sam Sydney, MD, Chief of Orthopedics at St. Agnes in Baltimore, MD, and a distinguished faculty will address the components every surgeon should evaluate when considering offering outpatient total joint replacement surgery as an option for their patients. Many patients suffering with painful joints do not want a lengthy hospital stay or recovery period that come from traditional joint replacement procedures. Technology like OMNINAV is designed to quickly return patients back to their active lifestyles.
About OMNIlife science, Inc. (OMNI)
OMNI is a privately held company with a proprietary robotic navigation platform, OMNINAV, which allows surgeons to conduct patient specific total knee surgery designed to enhance patient satisfaction, reduce hospital costs, and remove need for MRI and x-rays. This technology provides surgeons the much needed option to adjust during the procedure and is designed to provide an accurate customized fit. OMNI is an innovative and well-established hip and knee implant replacements engineering, manufacturing and distribution support company and is focused on providing cutting edge technologies to improve patient care.
Forward-Looking Statements
Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., (OMNI) including its advance robotic plans and statements using the terms “plans,” “confident” or similar expressions are “forward looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI’s markets, decrease in the demand for OMNI’s products, delays in OMNI’s product research and development cycles, decreases in the use of OMNI’s principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI’s current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI’s current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI’s sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI’s products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward looking statements after the date of this press release
Contact:
OMNIlife science, Inc. (OMNI)
Robert Phelps
Senior Vice President, Sales & Marketing
Phone: (508) 824-2444
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/omnilife-science-to-exhibit-at-american-association-of-hip-and-knee-surgeons-24th-annual-meeting-in-dallas-november-6-9-981261271.html
SOURCE OMNIlife science, Inc.
Help employers find you! Check out all the jobs and post your resume.
